Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Condition:   Large Granular Lymphocyte Leukemia
Intervention:   Drug: Siltuximab
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   EUSA Pharma, Inc.

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 8, 2022Comments | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine